GlassScriptPhysician profile
Miranda Lynn Gray
NPI 1982358412
$5,021.23
in general payments reported to CMS, 2019-2025
42 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $822 · 2023: $780 · 2024: $1,901 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,000 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.49 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $762.28 | 2022-2025 | Imjudo, Imfinzi, Enhertu |
| Myriad Genetic Laboratories, INC. | $385.51 | 2022-2025 | Myrisk |
| Abbvie INC. | $358.15 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $346.99 | 2022-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $344.62 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Incyte Corporation | $334.14 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $180.69 | 2023 | Imbruvica, Epkinly |
| Pfizer INC. | $149.01 | 2022-2025 | |
| Seagen INC. | $141.53 | 2022-2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $139.44 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $137.09 | 2022-2025 | Tecvayli, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $130.23 | 2023-2025 | |
| Lilly USA, LLC | $129.98 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $127.53 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Tempus Ai, INC | $122.06 | 2024-2025 | Xt Cdx |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.